This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (24)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Paul H. Kalina, MD; Jay C. Erie, MD; Louis Rosenbaum, MD

Arch Ophthalmol. 1995;113(7):867-869.

Abstract
Objective
To biochemically quantify the amount of active triamcinolone acetonide remaining after subconjunctival administration and to assess the effectiveness of surgical management for glaucoma induced by triamcinolone.

Design
Case series.

Participants
Seven eyes of seven patients whose ages ranged from 47 to 84 years underwent excision of depot triamcinolone. Six of seven eyes required surgical intervention for medically unresponsive intraocular pressure (IOP) elevation.

Results
Pharmacologically active triamcinolone was identified up to 13 months following injection (range, 3 to 13 months). The mean amount in the excised sample was 5.4 mg (range, 2.0 to 8.8 mg), and the mean percentage of the original sample remaining was 20% (range, 4.2% to 44%). Glaucoma was diagnosed a mean of 3 months after injection (range, 1 to 6 months). Mean IOP was 37 mm Hg before excision and 16 mm Hg after removal. Surgical excision of visible triamcinolone normalized IOP in six of seven patients without need for glaucoma medications.

Conclusions
Periocular injection of triamcinolone necessitates careful monitoring of IOP. Medically unresponsive IOP elevation may occur as late as 6 months following periocular triamcinolone injection. Surgical excision of remaining triamcinolone depot is an effective therapy for IOP elevation. Guidelines for safely using triamcinolone are discussed.

Author Affiliations
From the Department of Ophthalmology, Mayo Clinic Scottsdale (Ariz) and Mayo Clinic Foundation (Dr Kalina), and the Department of Ophthalmology, Mayo Clinic Rochester (Minn) and Mayo Clinic Foundation (Dr Erie). Dr Rosenbaum is in private practice in Phoenix, Ariz.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Failure-to-Thrive in an Infant Following Injection of Capillary Hemangioma With Triamcinolone Acetonide
DeBoer and Boston
CLIN PEDIATR 2008;47:296-299.
 

Intraorbital Injection of Triamcinolone Acetonide in Patients With Idiopathic Orbital Inflammation
Leibovitch et al.
Arch Ophthalmol 2007;125:1647-1651.
ABSTRACT | FULL TEXT  

Safety of an Intravitreal Injection of Triamcinolone: Results From a Randomized Clinical Trial
Gillies et al.
Arch Ophthalmol 2004;122:336-340.
ABSTRACT | FULL TEXT  

Biochemical Quantification of Triamcinolone in Subconjunctival Depots
Goldstein et al.
Arch Ophthalmol 1996;114:363-364.
ABSTRACT